ASCO 2023 | Vaccine approaches to immune modulation
Lana Kandalaft
• 4 Jun 2023
Lana Kandalaft, PhD, PharmD, MTR, University of Lausanne, Lausanne, Switzerland, highlighting the immunomodulatory role of vaccines in cancer treatment, emphasizing the recent advancements in the field of vaccines and their potential to improve clinical outcomes. Dr Kandalaft additionally highlights the ability of vaccines to prime T-cells, which can be used in combination with other treatments for enhanced efficacy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So I’ll be talking about vaccines and their immunomodulatory role in cancer treatment...
So I’ll be talking about vaccines and their immunomodulatory role in cancer treatment. So basically, so as you know, vaccines have have been around for a while and we have experienced a lot of failures. But recently the field has really exploded and we have now new improvements in the field. So I’ll be talking about how these vaccines, how the new technologies have now improved the vaccinations, how now we can combine vaccines with other treatments and improve clinical outcomes, how we can select better antigens and therefore create better vaccines. And finally, I’ll be talking about how vaccines can actually prime T cells and how we can use this in combination.
Read more...
The content of VJOncology is intended for healthcare professionals